Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | C1S | P09871 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679635 | 0.89 | — | — | |
| SCHEMBL23108146 | 0.79 | ESR2 (0.35) | ALDH1A1TSHRDPP4 | |
| SCHEMBL1514862 | 0.79 | HRH4 (0.41) | ALDH1A1TSHRHRH4KMT2ACCNA2 | |
| SCHEMBL23108145 | 0.79 | ESR2 (0.35) | ALDH1A1TSHRDPP4 | |
| Hydrochloric Acid SCHEMBL3646919 | 0.78 | HRH4 (0.40) | HRH4KMT2A | |
| Bromide SCHEMBL20292179 | 0.78 | HRH4 (0.40) | HRH4KMT2ACCNA2CDK2CCNA1 | |
| SCHEMBL17001830 | 0.76 | PLG (0.40) | ALDH1A1TSHRDPP4HTR6HRH4 | |
| SCHEMBL19937938 | 0.70 | QDPR (0.43) | ALDH1A1DPP4 | |
| SCHEMBL5667309 | 0.68 | SCN9A (0.44) | KMOABL1CYP11B2 | |
| SCHEMBL17760501 | 0.65 | SCN9A (0.37) | TSHRDPP4HTR6HRH4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| EP-3323815-B1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-07-02 | — | — | US | disclosed |
| US-20200108080-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-04-09 | — | — | US | disclosed |
| EP-3607821-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-2967066-B1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556367-A1 | BENZOSULFONAMIDE DERIVATIVES, COMPOSITIONS THEREOF, AND THEIR USE IN THE TREATMENT OF CANCER OR METASTASIS | Aerpio Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20130331386-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2013-12-12 | — | — | US | disclosed |
| US-8569348-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2592072-A2 | Human protein tyrosine phosphatase inhibitors and their use | Warner Chilcott Company, LLC (PR) | 2013-05-15 | — | — | EP | disclosed |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
| US-7622593-B2 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2041102-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter & Gamble Company (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2008002569-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | KMO 2022/4885L3MBTL1 3091/4885ALDH1A1 3159/4885 |
| US-20200108080-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | KMO 1643/4885L3MBTL1 3845/4885ALDH1A1 3546/4885 |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | KMO 4441/4885L3MBTL1 1016/4885ALDH1A1 292/4885 |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | KMO 2241/4885L3MBTL1 1026/4885ALDH1A1 1389/4885 |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | KMO 2022/4885L3MBTL1 3091/4885ALDH1A1 3159/4885 |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | KMO 2241/4885L3MBTL1 1026/4885ALDH1A1 1389/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | KMO 2241/4885L3MBTL1 1026/4885ALDH1A1 1389/4885 |
| US-20130331386-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | KMO 2241/4885L3MBTL1 1026/4885ALDH1A1 1389/4885 |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | VASP, DUSP15, PPP5C | KMO 4793/4885L3MBTL1 4695/4885ALDH1A1 3961/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | KMO 2352/4885L3MBTL1 4715/4885ALDH1A1 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.